Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.Molecular oncology · 2019
   Trial
2. Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.Cancers · 2022
   Review
3. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.Cancers · 2022
   Review
4. Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach.RSC advances · 2022
   Article
5. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.Drugs · 2022
   Review
6. Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer.Frontiers in oncology · 2022
   Review
7. Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.Journal of Cancer · 2022
   Article
8. Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer.Cancers · 2021
   Article
9. Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review.Oncology and therapy · 2020
   Article
10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.Thoracic cancer · 2020
    Article
11. Canadian consensus: a new systemic treatment algorithm for advancedCurrent oncology (Toronto, Ont.) · 2020
    Article
12. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.Translational lung cancer research · 2019
    Review
13. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.British journal of cancer · 2019
    Review
14. Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.American journal of cancer research · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as